常用中医外治法治疗变应性鼻炎的疗效观察

注册号:

Registration number:

ChiCTR2400082854 

最近更新日期:

Date of Last Refreshed on:

2024-04-09 17:25:47 

注册时间:

Date of Registration:

2024-04-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

常用中医外治法治疗变应性鼻炎的疗效观察

Public title:

Observation on the therapeutic effect of commonly used external treatment methods in traditional Chinese medicine for allergic rhinitis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

常用中医外治法治疗变应性鼻炎的疗效观察

Scientific title:

Observation on the therapeutic effect of commonly used external treatment methods in traditional Chinese medicine for allergic rhinitis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龚元戎 

研究负责人:

关玲 

Applicant:

Yuanrong Gong 

Study leader:

Ling Guan 

申请注册联系人电话:

Applicant telephone:

+86 150 2156 5991

研究负责人电话:

Study leader's
telephone:

+86 135 2057 5830

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1040763661@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1040763661@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区复兴路28号

研究负责人通讯地址:

北京市海淀区复兴路28号

Applicant address:

28 Fuxing Road, Haidian District, Beijing

Study leader's address:

28 Fuxing Road, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

100039

研究负责人邮政编码:

Study leader's postcode:

100039

申请人所在单位:

解放军总医院第六医学中心

Applicant's institution:

The Sixth Medical Center of PLA General Hospital

研究负责人所在单位:

解放军总医院第六医学中心

Affiliation of the Leader:

The Sixth Medical Center of PLA General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HZKY-PJ-2023-50

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

解放军总医院第六医学中心

Name of the ethic committee:

The Sixth Medical Center of PLA General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-12-06 00:00:00

伦理委员会联系人:

李进让

Contact Name of the ethic committee:

Jinrang Li

伦理委员会联系地址:

北京市海淀区阜成路6号

Contact Address of the ethic committee:

6 Fucheng Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 66957608

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

解放军总医院第六医学中心

Primary sponsor:

The Sixth Medical Center of PLA General Hospital

研究实施负责(组长)单位地址:

北京市海淀区阜成路6号

Primary sponsor's address:

6 Fucheng Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian District

单位(医院):

解放军总医院第六医学中心

具体地址:

北京市海淀区阜成路6号

Institution
hospital:

The Sixth Medical Center of PLA General Hospital

Address:

6 Fucheng Road, Haidian District, Beijing

经费或物资来源:

Source(s) of funding:

no

研究疾病:

变应性鼻炎  

Target disease:

Allergic rhinitis

研究疾病代码:

Target disease code:

研究类型:

治疗研究

Study type:

Treatment study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究拟通过对常用中医外治法(体针、耳穴等)治疗变应性鼻炎的疗效进行评价,筛选出适用于社会广泛开展的优效方案。  

Objectives of Study:

This study aims to evaluate the efficacy of commonly used traditional Chinese medicine external treatment methods (body acupuncture, ear acupoints, etc.) in the treatment of allergic rhinitis, and screen out effective plans that are widely applicable in society.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①有慢性副鼻窦炎病史,或经X线片检查发现患有慢性副鼻窦炎者; ②有鼻腔器质性病变或曾经行鼻腔手术者; ③过去1年内曾接受激素系统治疗者; ④合并有呼吸系统其他疾病者,如支气管扩张、肺部恶性病变等; ⑤合并有肝肾功能不全、严重精神心理疾患或其他严重疾病者; ⑥对研究中使用的相关药物过敏或晕针者; ⑦妊娠或哺乳期妇女。

Exclusion criteria:

① Individuals with a history of chronic sinusitis or those diagnosed with chronic sinusitis through X-ray examination; ② Individuals with organic lesions in the nasal cavity or those who have undergone nasal surgery; ③ Individuals who have received hormone therapy within the past year; ④ Individuals with concomitant respiratory system diseases, such as bronchiectasis, malignant lung lesions, etc; ⑤ Individuals with combined liver and kidney dysfunction, severe mental and psychological disorders, or other serious illnesses; ⑥ Individuals who have allergies or fainting to the relevant drugs used in the study; ⑦ Pregnant or lactating women.

研究实施时间:

Study execute time:

From 2024-05-01 00:00:00 To 2025-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-01 00:00:00 To 2025-05-31 00:00:00

干预措施:

Interventions:

组别:

蝶腭神经节针刺组

样本量:

50

Group:

Acupuncture group of sphenopalatine ganglion

Sample size:

干预措施:

取颧骨弓的下缘为进针点, 即为颞骨颧突和颧骨颞突的合缝线隆起部的稍后位置, “下关”穴前方约1.5cm, 此处能触及一弓形凹陷, 使用长55mm, 粗0.35mm的针灸针从弓形凹陷中央下方进针, 针尖稍微斜向前上方缓慢刺入, 途中调节合适方向, 避开面部多重骨组织, 最终针身将全数没入皮内, 患者针侧面颊部可能产生强烈窜电感或亦有描述为鼻腔内出现瞬间的喷水样感觉。反复适度刺激3~5次后起针。针刺双侧蝶腭神经节,1次/周,治疗1周。

干预措施代码:

Intervention:

Take the lower edge of the zygomatic arch as the needle entry point, which is the later position of the ridge of the joint line of the zygomatic process of the temporal bone and the temporal process of the zygomatic bone. About 1.5cm in front of the "Xiaguan" point, a bow shaped depression can be reached here. Use a 55mm long and 0.35mm thick acupuncture and moxibustion needle to enter the needle from below the central part of the bow shaped depression. The needle tip is slightly inclined forward and upward and slowly inserted. Adjust the appropriate direction on the way to avoid multiple bone tissues on the face. Finally, the needle body will be totally immersed in the skin. The patient's cheek on the side of the needle may have a strong channeling inductance or it is also described as a momentary spray like feeling in the nasal cavity. Repeatedly stimulate moderately for 3-5 times before starting the injection. Acupuncture of bilateral sphenopalatine ganglia, once per week, treatment for one week.

Intervention code:

组别:

传统针刺组

样本量:

50

Group:

Ordinary acupuncture group

Sample size:

干预措施:

取双侧足三里穴(在外膝眼下3寸,胫骨前棘旁开1寸)、双侧丰隆穴(外踝尖上8寸,距胫骨前缘二横指)、双侧血海穴(髌底内侧端上2寸,股内侧肌隆起处)、双侧太溪穴(内踝尖与跟腱之间的凹陷中),患者取仰卧位,针刺处皮肤消毒,用 1.5 寸针灸针,直刺入,针尖与皮肤呈 90°,进针后行针5分钟,留针20分钟,隔日1次,1周内治疗3次,治疗1周。

干预措施代码:

Intervention:

Take bilateral Zusanli points (3 inches below the outer knee, 1 inch beside the anterior spine of the tibia), bilateral Fenglong points (8 inches above the outer ankle tip, two transverse fingers from the front edge of the tibia), bilateral Xuehai points (2 inches above the medial end of the patellar base, at the bulge of the medial thigh muscle), and bilateral Taixi points (in the depression between the inner ankle tip and the Achilles tendon). The patient takes a supine position, disinfects the skin at the acupuncture point, and uses a 1.5 inch acupuncture and moxibustion needle to directly puncture the needle tip at a 90 ° angle to the skin. The needle is inserted for 5 minutes, retained for 20 minutes, treated once every other day, treated three times within a week, and treated for one week.

Intervention code:

组别:

耳穴贴压组

样本量:

50

Group:

Ear acupoint pressing group

Sample size:

干预措施:

选取双侧内鼻、肺、脾、肾、内分泌。穴位定位参照《中华人民共和国国家标准·耳穴名称与定位》。将耳廓及耳周常规消毒后,一手固定耳廓,另一手持镊在穴位上贴压王不留行籽,固定后按压数次,以耳部酸胀疼痛为度,并嘱受试者每日自行按压3~5次,每次每穴按压约2~3min,治疗1周。

干预措施代码:

Intervention:

Select bilateral ‘neibi’,‘fei’,'pi', 'shen', and 'neifenmi'. Acupoint positioning shall refer to the National Standard of the People's Republic of China for Ear Acupoint Names and Positioning. After routine disinfection of the auricle and ear area, one hand should fix the auricle, and the other hand should hold tweezers to apply pressure on the acupoints. After fixation, press several times to relieve ear soreness and pain. The subjects should be instructed to self press 3-5 times a day, each time for about 2-3 minutes per acupoint, for one week of treatment.

Intervention code:

组别:

简化耳穴贴压组

样本量:

50

Group:

Simplified ear acupoint pressing group

Sample size:

干预措施:

选取双侧内鼻及风溪。穴位定位参照《中华人民共和国国家标准·耳穴名称与定位》。将耳廓及耳周常规消毒后,一手固定耳廓,另一手持镊在穴位上贴压王不留行籽,固定后按压数次,以耳部酸胀疼痛为度,并嘱受试者每日自行按压3~5次,每次每穴按压约2~3min,治疗1周。

干预措施代码:

Intervention:

Select bilateral 'neibi' and 'fengxi'. Acupoint positioning shall refer to the National Standard of the People's Republic of China for Ear Acupoint Names and Positioning. After routine disinfection of the auricle and ear area, one hand should fix the auricle, and the other hand should hold tweezers to apply pressure on the acupoints. After fixation, press several times to relieve ear soreness and pain. The subjects should be instructed to self press 3-5 times a day, each time for about 2-3 minutes per acupoint, for one week of treatment.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

海淀 

Country:

China

Province:

Beijing

City:

Haidian District

单位(医院):

解放军总医院第六医学中心 

单位级别:

三级甲等 

Institution
hospital:

The Sixth Medical Center of PLA General Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

鼻部症状积分量表

指标类型:

主要指标

Outcome:

total nasal symptom score

Type:

Primary indicator

测量时间点:

治疗前,治疗后第2天,疗程结束后,疗程结束后2周,疗程结束后4周

测量方法:

问卷调查

Measure time point of outcome:

Before treatment, on the second day after treatment, after the end of the course, 2 weeks after the end of the course, and 4 weeks after the end of the course

Measure method:

questionnaire survey

指标中文名:

鼻炎伴随症状积分量表

指标类型:

次要指标

Outcome:

total non-nasal symptom score

Type:

Secondary indicator

测量时间点:

治疗前,治疗后第2天,疗程结束后,疗程结束后2周,疗程结束后4周

测量方法:

问卷调查

Measure time point of outcome:

Before treatment, on the second day after treatment, after the end of the course, 2 weeks after the end of the course, and 4 weeks after the end of the course

Measure method:

questionnaire survey

指标中文名:

鼻结膜炎生存质量调查问卷

指标类型:

次要指标

Outcome:

rhinoconjunctivitis quality of life questionnaire, RQLQ

Type:

Secondary indicator

测量时间点:

治疗前,疗程结束后,疗程结束后2周,疗程结束后4周

测量方法:

问卷调查

Measure time point of outcome:

Before treatment,after the end of the course, 2 weeks after the end of the course, and 4 weeks after the end of the course

Measure method:

questionnaire survey

指标中文名:

视觉模拟量表

指标类型:

次要指标

Outcome:

visual analogue scale

Type:

Secondary indicator

测量时间点:

治疗前,治疗后第2天,疗程结束后,疗程结束后2周,疗程结束后4周

测量方法:

问卷调查

Measure time point of outcome:

Before treatment, on the second day after treatment, after the end of the course, 2 weeks after the end of the course, and 4 weeks after the end of the course

Measure method:

questionnaire survey

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用采用SPSS 26.0 生成随机数表。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study used SPSS 26.0 to generate a random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

由于针刺手法的特殊性,具体操作中无法实现对治疗师和受试者的双盲,因此本实验采用数据分析者忙的方法,由对分组情况毫不知情的第三方数据统计分析人员完成数据的采集和统计分析工作。

Blinding:

Due to the particularity of acupuncture techniques, it is not possible to achieve double-blind treatment for both the therapist and the subjects in the specific operation. Therefore, this experiment adopts the method of busy data analysts, and third-party data statistical analysts who are unaware of the grouping situation complete the data collection and statistical analysis work.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台ResMan(www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan(www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

临床试验公共管理平台ResMan(www.medresman.org.cn)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan(www.medresman.org.cn)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-04-09 17:25:44